Increased Education and Early Detection of Fatty Liver Disease
Read More
Highlights Value of Non-Invasive Screening for Fatty Liver Disease
FibroScan will be included in over 163 abstracts including 18 oral presentations that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings
Given the shift to value-based medicine and the significant cost implications of NASH, the study explored which outcomes and quality measures KOLs would recommend for value-based contracting.
Pilot Study Underway Identifies Patients with Progressive Non-Alcoholic Fatty Liver Disease
Twin Epidemics Call for Early Detection, Monitoring and Lifestyle Changes
Researchers will present over 160 peer reviewed posters and oral presentations that include FibroScan during The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD)
In support of Liver Cancer Awareness Month alongside the American Liver Foundation, Echosens calls for increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH)
